X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Burosumab
Therapeutic Area: Genetic Disease Product Name: Crysvita
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2021
Details:
The Committee indicated that, if a patient is receiving a stable dose of Crysvita (burosumab), their treating physician can then recommend that administration be performed by the patient or their carer following training.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lanadelumab
Therapeutic Area: Genetic Disease Product Name: Takhzyro
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Results were consistent with the safety and efficacy of TAKHZYRO in the pivotal trial. The HELP Study OLE was designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO for up to 2.5 years.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Burosumab
Therapeutic Area: Genetic Disease Product Name: Crysvita
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
CRYSVITA, created by Kyowa Kirin, is a recombinant fully human monoclonal IgG1 antibody against the FGF23. More people in Europe are now eligible for treatment with CRYSVITA, the only therapy that targets the underlying pathophysiology of XLH.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Porcine recombinant Factor VIII
Therapeutic Area: Genetic Disease Product Name: Obizur
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: HLS Therapeutics
Deal Size: $49.3 million Upfront Cash: $30.8 million
Deal Type: Acquisition September 30, 2020
Details:
HLS has acquired certain entities that hold the rights to a diversified portfolio of royalty interests on global sales of four different products, this includes Takeda Pharmaceutical's Obizur, a porcine recombinant Factor VIII for acquired hemophilia A.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
